International Prostate Cancer Update 2021 Session Review: Biomarkers and Genetic Testing

Posted by Alan H. Bryce, MD | Nov 2021

Alan H. Bryce, MD, summarizes talks from the session he moderated on Biomarkers and Genetic Testing during the 31st International Prostate Cancer Update in July 2021 in Snowbird, Utah. See below for links to full presentations from the conference as well as related panel discussions.

How to cite: Bryce, Alan H. “International Prostate Cancer Update 2021 Session Review: Biomarkers and Genetic Testing.” July 2021. Accessed Apr 2024. https://grandroundsinurology.com/international-prostate-cancer-update-2021-session-review-biomarkers-and-genetic-testing/

Lectures from this Session:

Prostate Cancer Early Detection 2021 – Peter R. Carroll, MD, MPH, discusses guidelines and research on prostate cancer early detection and ways to avoid unnecessary biopsies.

What’s New in Active Surveillance for Prostate Cancer in 2021 – Laurence Klotz, MD, FRCSC, discusses recent developments in active surveillance for prostate cancer, highlighting its efficacy.

Genetic Testing and Prostate Cancer – Raoul S. Concepcion, MD, FACS, discusses genomics & DNA repair with the goal of improving PCa treatment & use of next generation sequencing.

Germline Genetics in Prostate Cancer – Brian T. Helfand, MD, PhD, discusses how physicians can effectively use germline genetics for prostate cancer diagnosis and prognosis.

Prostate Cancer Risk Assessment: Focus on Early PSA and Hereditary Risk – Gerald L. Andriole, Jr., MD, discusses two areas of prostate cancer risk assessment – age-adapted PSA and hereditary risk.

Use of Polygenic Risk Scores for Prostate Cancer Screening – Peter R. Carroll, MD, MPH, discusses the use of polygenic risk scores to improve upon PSA for prostate cancer screening.

Review of Sentinel Assay for Prostate Cancer Diagnosis – Laurence Klotz, MD, FRCSC, reviews the Sentinel Assay, a urine-based assay for detecting prostate cancer currently awaiting FDA approval.

Session 2 Panel Discussion:

Alan H. Bryce, MD, moderates a panel discussion focused on biomarkers and genetic testing for prostate cancer. The panel features Laurence Klotz, MD, FRCSC, A. Karim Kader, MD, PhD, Brian T. Helfand, MD, PhD, Raoul S. Concepcion, MD, FACS, and Peter R. Carroll, MD, MPH.

How to cite: Bryce, Alan H. “Panel Discussion: Biomarkers and Genetic Testing.” July 2021. Accessed Apr 2024. https://grandroundsinurology.com/international-prostate-cancer-update-2021-session-review-biomarkers-and-genetic-testing/

About The 31st Annual International Prostate Cancer Update:

The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The educational activities featured here were presented during the 31st iteration of the meeting in July 2021 in Snowbird, Utah.

About The Author

Alan H. Bryce, MD

Alan H. Bryce, MD, is a medical oncologist and chief clinical officer at City of Hope in Phoenix, Arizona. Dr. Bryce holds an appointment as a professor with the Department of Medical Oncology & Therapeutics Research, with City of Hope, as well as an appointment as a professor of Molecular Medicine at Translational Genomics Research Institute (TGen), which is also part of City of Hope. Prior to joining City of Hope, Dr. Bryce spent 12 years at the Mayo Clinic in Phoenix, where he served as chair of the Division of Hematology and Medical Oncology, as well as Director of the Mayo Clinic Arizona Comprehensive Cancer Center. Dr. Bryce received his medical degree from the Chicago Medical School, and then completed an internal medicine residency and a hematology and oncology fellowship at the Mayo Clinic in Rochester, Minnesota. During his time at Mayo, Dr. Bryce served as an international co-principal investigator on multiple clinical trials for prostate cancer, with his research focused on cancer genetics, novel therapies and immunotherapeutic approaches.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat